The program is designed to support innovative translational research projects in hematologic malignancies that can be based around either a clinical trial or laboratory investigation.
Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap or duplication in funding.
All proposals are reviewed based upon the criteria outlined on this website. There is no Commercial involvement in the review and selection of award recipients, i.e., no Marketing, Sales, or Commercial Strategy involvement.